Aflac AFL
Financial Services · Insurance - Life · Synthos Deep Dive · 2026-07-03
The Overview
Aflac is the duck-commercial company. It sells supplemental insurance — the extra policies that pay you cash if you get cancer, have an accident, or land in the hospital, on top of your regular health plan. Most of its money actually comes from Japan, not the US, which surprises people. It is a very well-run, very safe company: almost no debt, and it has been steadily buying back its own shares and raising its dividend for decades.
The problem is growth. The Japanese business is slowly shrinking, and a weak Japanese yen makes it look even smaller in US dollars. So even though the company is excellent, its profits are barely growing — only a few percent a year. And right now the stock is at its highest price of the year, actually a touch above what Wall Street analysts think it's worth.
Our verdict is Watch: a great company, but you're paying a full price for something that isn't growing much. Better to wait for a cheaper entry than to chase it here.
Here's what our three scores mean in everyday terms:
- Downside Risk 4/10 (fairly safe). Rock-solid finances and a stock that doesn't swing much — but it's priced at a high, so there's little cushion if results disappoint.
- Growth Quality 4/10 (below average). The company is profitable and disciplined, but the top line is actually shrinking and profit growth is thin.
- Exponential Potential 2/10 (very low). This is a mature, slow-and-steady business. Do not expect it to multiply your money — it's an income holding, not a rocket.
The one big worry: most of the business is in Japan, where the customer book is maturing and the yen keeps eroding the dollar value of those profits.
Putting a number on it: our fair-value estimate is $114 against a current price of $116.52 — consistent with our call to stay away or wait for a better setup.
Our summary metrics
Fortress balance sheet, 0.34× net-debt/EBITDA & 0.61 beta — but at a 52-wk high above the Street's target, with structural yen/Japan drag.
Only ~4–5% forward EPS CAGR, revenue shrinking in reported $, growth is buyback-driven not organic.
Mature supplemental-insurer; low-teens EPS growth decelerating, TAM saturated, no acceleration — the opposite of exponential.
What does “fair value” mean?
Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.
The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, plus an independent, public-math cross-check further down the page (“Check our number”) so you can judge it for yourself.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Exponential Potential
Mature supplemental-insurer; low-teens EPS growth decelerating, TAM saturated, no acceleration — the opposite of exponential.
What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.
Deeper analysis
Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.
Reference table
| Street consensus | $114.40 (high $130 / low $99; 9 Buy · 18 Hold · 5 Sell — "Hold") — context, not our anchor |
| Valuation | 13.7× trailing EPS · 17× FY26E · 16× FY27E · P/B 2.1× · EV/EBITDA 9.6× |
| Technicals | Uptrend but stretched — $120.88 at the 52-wk high, above 50/200-DMA, RSI 62, +14% 12-mo (SPY +21%) |
| Conviction | Low — 0 expert voices, 0 traceable claims in the Synthos KB; call rests on fundamentals + quant only |
| Position sizing | If owned at all: income/defensive satellite, ~1–2% — not a growth holding |
What the experts actually said
No independent expert claims in the Synthos knowledge base yet for AFL — this dive is fundamentals- and technicals-driven, not panel-driven.
Price & moving averages 12 months · 50 & 200-day averages · 52-week range
Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.
Data summary: last close $116.52, 4% below the 50-day average ($122), 2% above the 200-day average ($114) — a mixed trend. 10% below the 52-week high of $130, 10% above the 52-week low of $106.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Data summary: price $116.52 is currently inside the band (band $113–$128).
RSI (14) momentum gauge · 0–100
Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 38.
MACD 12 / 26 / 9 · trend & momentum
The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.
Data summary: MACD is currently below its signal line by 0.54, negative momentum.
Relative performance vs S&P 500 & its sector (XLF (sector)), set to 100 a year ago
Solid = AFL · dashed = S&P 500 · dotted = XLF (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
1. What it is
Aflac Incorporated (NYSE: AFL), founded 1955 and headquartered in Columbus, Georgia, is a supplemental health and life insurer that operates through two core segments: Aflac Japan and Aflac U.S. In Japan it is the leading seller of cancer and medical insurance, plus income-support/nursing-care products and savings-oriented life plans (WAYS, child endowment). In the US it sells cancer, accident, short-term disability, critical-illness, hospital, dental, vision, life and disability policies, distributed through sales associates and brokers largely at the worksite. Fiscal year ends December 31.
Segment revenue (FY2025, from filings):
- Aflac Japan $9.36B (53%) · Aflac US $6.90B (39%) · Other $1.28B (7%). Japan is still the larger book but it is shrinking (FY22 $12.25B → FY23 $10.66B → FY24 $9.66B → FY25 $9.36B), while the US grows slowly (FY22 $6.49B → FY25 $6.90B). This mix shift — a declining, yen-exposed Japan book against a slow-growing US book — is the whole story on the top line.
- By geography (FY2025): Japan $9.36B · US $6.90B. The concentration in Japan (yen functional currency) is the defining structural feature — and risk.
Note on the numbers: AFL is an insurer, so GAAP "revenue" and quarterly EPS are noisy — they swing with yen translation, market-driven remeasurement of reserves, and investment marks. Management steers on adjusted EPS ex-currency (Q1'26 adjusted EPS $1.77, +6.6% ex-FX). We flag this throughout: trailing GAAP EPS ($6.86) understates the run-rate; the ~$8.80 TTM diluted figure and Street's ~$7.60 FY26E adjusted number are the fairer earnings-power reads.
2. The expert thesis (traceable)
There is no expert coverage of AFL in the Synthos knowledge base. total_claims = 0, net_bullish_voices = 0. No distilled voice — bullish or bearish — has an on-record, reconciled view on Aflac in our system.
Accordingly, this verdict is fundamentals- and quant-driven only, and we say so plainly. There are no claim_id values to cite, and we will not manufacture conviction we do not have. Everything below is derived from the FMP financial data, analyst consensus estimates (labeled as estimates), the company's own SEC filings, and the price/technical block — nothing else.
For context (not KB conviction), the sell-side is lukewarm: 9 Buy / 18 Hold / 5 Sell → a "Hold" consensus, with a price target ($114.40) that sits below the current $120.88 quote. The independent quant letter rating is A- (strong balance sheet and returns, mediocre on P/E and P/B). Neither is an expert-panel signal; both corroborate the "quality but full" read.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (lower = safer) | 4 · Moderate-Low | Net-debt/EBITDA 0.34×, beta 0.61, A- balance-sheet rating, tiny drawdown — genuinely defensive. Marked up off the floor because it's at a 52-wk high, trades above the Street target, and carries structural yen/Japan and a flagged June-2025 cyber incident. |
| Growth Quality | 4 · Below-Average | ~4–5% forward EPS CAGR, reported revenue shrinking, ROE ~16% but ROIC only ~4%. Discipline is real; organic growth is not. Growth is largely manufactured by a ~26% five-year share-count reduction. |
| Exponential Potential | 2 · Low | Mature supplemental insurer, saturated core TAM, decelerating low-single-digit growth, no acceleration anywhere. The structural opposite of an exponential. |
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. Instead the cases bound the range, and the scores above summarize them.
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | Yen stabilizes/strengthens (tailwind flips), US premium growth holds ~4–5%, buyback continues shrinking the float. FY28E EPS ~$8.0; multiple re-rates to ~16× on FX relief. | ~$128 (+6%) |
| Base (our anchor) | Estimates roughly hit — FY27E adjusted EPS ~$7.59; a low-growth, high-quality insurer earns its historical ~15×. | ~$114 (−6%) |
| Bear | Yen weakens further, Japan book keeps eroding, a reserve/credit miss or renewed cyber fallout. FY27E EPS ~$7.5; multiple de-rates to ~11× (its historical low). | ~$88 (−27%) |
Synthos fair value = the base case, ~$114 (−6%), with the full $88–$128 span as the honest range. This anchor lands essentially on the Street's $114.40 consensus — an unusual case where our independent model and the sell-side agree the stock is already at fair value. There is no margin of safety at $120.88; the stock is trading above both anchors. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). AFL is neither an exponential nor even a growth compounder — it is a mature, capital-return story:
- Forward growth: consensus EPS $7.07 (FY26E) → $7.59 (FY27E) → $7.98 (FY28E) → $8.20 (FY29E) — a ~5% EPS CAGR off the 2026 base, and only ~2%/yr off the 2025 estimate. Reported revenue is flat-to-down ($17.66B FY25E → ~$17.4B FY29E consensus).
- Acceleration (the 2nd derivative) is flat-to-negative: there is no inflection anywhere in the estimate curve. Japan premium is declining (underlying earned premium −1.3% in Q1'26); US premium grows low-single-digits (+3.5%). Per our flagship philosophy we hunt forward next-exponentials — AFL is the trailing-compounder archetype we explicitly avoid overpaying for.
- Room to run: the supplemental-insurance TAM in its two markets is mature and largely penetrated. At $61.5B market cap the company is not TAM-constrained by size, but there is no large untapped demand pool to expand into either. Growth is a share-of-wallet and pricing grind, not a land-grab.
- Reinvestment runway: minimal. The company can't productively reinvest its cash at high rates (ROIC ~4%), which is why it returns nearly all of it via buybacks and dividends. That's shareholder-friendly, but it's the signature of a no-growth business.
Exponential Potential: Low (2/10). Own AFL — if at all — for its ~2% dividend, decades-long payout growth, and the mechanical EPS lift from relentless buybacks. Do not own it expecting a multibagger; the numbers foreclose it.
5. Financials (real numbers — FMP annual/quarterly)
- Revenue: FY25 GAAP $17.44B, down from FY24 $19.13B and FY23 $18.84B — a multi-year decline driven by yen translation and reinsurance/paid-up dynamics in Japan. The reported top line is not growing.
- Segment trend (the tell): Japan $9.36B and eroding; US $6.90B and slowly rising. The US now supplies the only organic growth.
- Margins: TTM net margin ~25%, EBITDA margin ~37%, gross ~48%. For a supplemental insurer these are strong and stable — profitability is not the problem.
- Earnings: FY25 GAAP net income $3.65B, EPS $6.86 ($6.83 diluted). GAAP was depressed by 2025 volatility (Q1'25 EPS just $0.05 on market marks); the cleaner TTM diluted figure is ~$8.80, and management's adjusted Q1'26 EPS was $1.77 (+6.6% ex-FX). Use the adjusted/TTM lens, not the noisy GAAP print.
- Cash flow: FY25 operating & free cash flow ~$2.56B (FCF yield ~4.8%). Ample to fund the dividend (~$1.20B) and buyback (~$3.53B repurchased in FY25).
- Balance sheet: total debt $8.41B against $6.25B cash + a $97.5B investment portfolio; net debt just $2.16B → net-debt/EBITDA 0.34×. Debt/equity 0.26×, interest coverage ~24×. A genuine fortress — the core of the low Downside Risk score.
- Capital return: shares outstanding fell from ~714M (2020) to ~530M (2025) — a ~26% reduction, the single biggest driver of per-share earnings growth. Dividend $2.38/yr, ~26% payout — decades of increases (a dividend-aristocrat profile).
6. Valuation — priced in or room?
AFL is not cheap and not egregiously expensive — it's fully valued. On the noisy trailing GAAP EPS it's 17.6× ($120.88 / $6.86); on the cleaner TTM diluted earnings power (~$8.80) it's 13.7×; on forward consensus it's 17.1× FY26E ($7.07) and 15.9× FY27E ($7.59). Historically AFL has traded in a ~9–13× band as a slow-growth insurer, so today's mid-teens forward multiple is at the high end of its own history for a business whose revenue is shrinking.
Other reads: P/B 2.07× (rich for a life insurer, which often trade near or below book), EV/EBITDA 9.6×, earnings yield ~7.5%, dividend yield ~2.0%. A reverse read: at 15× a ~$7.59 FY27E, the stock is worth ~$114 — so at $120.88 the market is already paying for FY27's earnings today.
Street targets (context): consensus $114.40, high $130, low $99, "Hold" (9/18/5). Our independent base-case FV of ~$114 essentially matches it — a rare full alignment that the stock is at fair value with no margin of safety at the current quote. Not a value buy; a quality-at-full-price, wait-for-a-pullback name.
7. Technicals (from the tech block)
- Trend: up but extended. $120.88 sits above the 50-DMA ($116.07) and 200-DMA ($111.95), 50 above 200 (golden-cross posture), MACD +1.08 (mildly positive).
- Location: exactly at the 52-week high ($120.88) — 0% off the peak, +23% off the 52-week low ($98.09). A name pinned at highs has no technical cushion; a pullback is a better entry than a breakout chase.
- Momentum: RSI(14) 62 — firm but not yet overbought (<70). No extreme, but no bargain signal either.
- Relative strength (the tell): AFL +14.3% 12-mo vs SPY +20.6% and QQQ +30.3% — it has lagged both the market and (heavily) the Nasdaq over the past year. 3-mo +10.3% vs SPY +13.7% / QQQ +22.0% — still a laggard. This is a low-beta defensive that trails in up-tapes, exactly as its 0.61 beta implies.
- Read: technicals show a steady, low-volatility uptrend but no urgency to buy at the 52-week high and above the Street's target. A retreat toward the rising 50-DMA (~$116) or lower would be a more sensible entry.
8. Moat & competitive position
Aflac's moat is real but narrow: a dominant brand and worksite-distribution position in supplemental insurance (the duck is one of the most recognized insurance brands in the US, and Aflac is the category leader in Japan cancer/medical). Switching is low-friction for the customer, but Aflac's agent/broker relationships, worksite payroll-deduction plumbing, and scale create sticky distribution. Persistency is high (Japan 92.8%, US 79.3% in Q1'26). The offset: it's a mature, competitive, low-growth category with no technological edge and heavy exposure to Japanese demographics and the yen.
Peer set (market cap): MetLife $57.9B and Manulife $68.7B are the closest large-cap comps; Prudential Financial $39.2B, Prudential plc $34.4B, Unum $14.8B, Primerica $9.3B, Jackson Financial $7.3B, Lincoln National $7.1B, CNO $4.9B, F&G $3.7B, Brighthouse $3.7B round out the life/supplemental group. AFL commands a premium P/B (2.1×) to most of these — the market already pays up for its balance-sheet quality and capital-return discipline, which is precisely why there's little upside left in the multiple.
9. Management, capital allocation & guidance
- Capital allocation (the best part of the story): exemplary. ~26% share-count reduction in five years, a dividend-aristocrat payout history at a conservative ~26% payout, and near-zero net leverage. When a business can't reinvest at high returns, returning cash aggressively is the right call — and Aflac does it as well as any insurer.
- Insider / ownership activity: routine. Recent Form 4s show a director exercising and selling options (Moskowitz, June 2026) and Japan Post Holdings (a 10% owner) trimming its stake — Japan Post remains a large strategic holder; the sales are small relative to its ~51M-share position. No alarming discretionary insider cluster in the sampled window.
- Management's own guidance (half-weighted — their own book): the Q1'26 CFO earnings-call update (SEC 8-K, EX-99.3, dated 2026-04-29) is real forward-looking commentary and reads as a genuine release. Management's framing: adjusted EPS +6.6% YoY ex-FX to $1.77; adjusted ROE 16.4% ex-FX remeasurement (a "solid spread to cost of capital"); Japan pretax margin 35.0%, +320 bps YoY with a total benefit ratio of 62.9% and persistency 92.8%; US net earned premium +3.5% with persistency 79.3%. Management characterizes the quarter as "solid" and continues to steer on currency-neutral metrics — an implicit acknowledgment that the reported (yen-translated) numbers look weaker than the underlying. It also explicitly flags the June-2025 unauthorized-network-access (cyber) incident as an ongoing uncertainty. Treat as management's self-interested words, half-weight. No hard full-year EPS/revenue numeric guide was disclosed in this release.
10. Catalysts & what to watch
- Next earnings: 2026-08-06 (Q2'26; Street EPS $1.78, revenue ~$4.10B). Watch US premium growth (the only organic engine) and Japan underlying earned premium (is the −1.3% decline stabilizing?).
- Yen/dollar exchange rate: the single biggest swing factor for reported results — a stronger yen would flip a multi-year translation headwind into a tailwind (the crux of the bull case).
- Buyback pace: continued float shrinkage is the main EPS-growth lever; watch repurchase dollars each quarter.
- Reserve remeasurement & variable investment income: the source of GAAP noise; large swings either way move the print.
- June-2025 cyber incident: any escalation in cost, litigation, or regulatory action.
Thesis tripwires (what would change the call): a sustained yen strengthening + stabilizing Japan premium could turn this from Watch to Buy on a pullback; conversely, an accelerating Japan decline, a reserve/credit miss, or a de-rating below book-value support would confirm the Avoid tail.
11. Key risks
- Structural Japan/yen drag: ~53% of segment revenue is a maturing, yen-denominated book; further yen weakness suppresses reported earnings and book value.
- No organic growth: reported revenue is falling and EPS growth (~4–5%) leans on buybacks; if the buyback slows, per-share growth stalls.
- Valuation / no margin of safety: at a 52-week high, above the Street's own target and at the high end of its historical multiple, downside on any disappointment outweighs upside.
- Investment-portfolio & credit risk: a $97.5B portfolio backs the liabilities; credit downgrades, defaults, or rate shocks hit book value.
- Cyber / operational: the disclosed June-2025 unauthorized-network-access incident is an unresolved overhang.
- No expert coverage: with 0 KB claims, there is no independent conviction cross-check — the call rests entirely on the quant/fundamental read.
12. Verdict, position sizing & monitoring
Watch. Aflac is a genuinely excellent, fortress-balance-sheet, capital-return machine — but excellence is not the question; price for the growth on offer is. Reported revenue is shrinking, forward EPS growth is only ~4–5% and buyback-driven, and at $120.88 the stock sits at a 52-week high, above both the Street's $114.40 target and our independent ~$114 base-case fair value. There is no margin of safety and no expert-panel conviction (0 KB claims) to argue for paying up.
- Sizing: if held at all, an income/defensive satellite, ~1–2% — a low-beta dividend holding, not a growth allocation. We would want a pullback toward the low-$110s / high-$100s (or a yen-driven catalyst) before it becomes a Buy.
- Monitoring: re-underwrite on the §10 tripwires; formal re-score each earnings print. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $120.88.
- Single biggest risk: the structural Japan/yen drag on a maturing majority of the book.
Provenance & disclosures
- Traceability: 0 KB claims, breadth 0, no reconciled
claim_ids — this is an honest "no expert coverage" note. The verdict is fundamentals- and quant-driven only, and labeled as such. Fabricated conviction is structurally impossible (there are no claims to cite, and none are cited). - Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates & prices 2026-07-03 · no expert claims. Forward figures are analyst consensus (FMP) or our own scenario model, labeled as estimates.
- Management caveat: the Q1'26 CFO video-update guidance (SEC 8-K EX-99.3, 2026-04-29) is management's own book, half-weighted by design; no hard full-year numeric guide was disclosed.
- Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
- Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").